Preclinical study shows potential of new technologies to detect
response to cancer therapy earlier 3-D Ultrasound Molecular
Imaging (USMI) images of non-responder and responder pancreatic
xenografts before (day 0) and after (day 2) treatment. The
grayscale image shows a volume of the tumor and surrounding
tissue. The green region is the molecular sig The research was
published early in the January issue of the journal Technology
in Cancer Research and Treatment. The article describes
experiments using ultrasonic molecular imaging (USMI) and
Dynamic Contrast Enhanced-Perfusion Imaging (DCE-PI) to measure
response to therapy for pancreatic cancer. Paul Dayton, PhD,
senior author says, “ What we found is that using two non-
invasive technologies, we can detect response to therapy earlier
than by relying on tumor volume changes. Having new non-
invasive, inexpensive technologies available to measure response
to therapy earlier during the course of treatment would be a
significant advance in the ability to tailor a